Home > Publications Database > Ubiquitin Carboxyl-Terminal Hydrolases (UCHs): Potential Mediators for Cancer and Neurodegeneration. > print

001     153373
005     20240321221042.0
024 7 _ |a 10.3390/ijms21113910
|2 doi
024 7 _ |a pmid:32486284
|2 pmid
024 7 _ |a pmc:PMC7312489
|2 pmc
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
024 7 _ |a altmetric:83197227
|2 altmetric
037 _ _ |a DZNE-2020-01370
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Sharma, Amit
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Ubiquitin Carboxyl-Terminal Hydrolases (UCHs): Potential Mediators for Cancer and Neurodegeneration.
260 _ _ |a Basel
|c 2020
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1606141570_31361
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Emerging evidence suggests an inverse association between cancer and neurodegenerative diseases (NDD). Although phenotypically different, both diseases display a significant imbalance in the ubiquitination/deubiquitination processes. Therefore, we particularly investigated the expression of ubiquitin C-terminal hydrolases (UCHs: UCH-L1, UCH-L3, UCH-L5 and BAP1), a subfamily of deubiquitinating enzymes (DUBs), using publically available datasets (GTEx, TCGA) and observed altered expression of UCH-L1, UCH-L3, UCH-L5 in 17 cancer types. Interestingly, UCH-L1 (known to be enriched in neurons and interacting with the Parkinson's disease-associated protein α-synuclein) appeared to be a prognostic indicator of unfavorable outcome in endometrial and urothelial cancer, while increased expression of UCH-L3 and UCH-L5 was associated with poor survival in liver and thyroid cancer, respectively. In normal tissues, UCH-L1 was found to be strongly expressed in the cerebral cortex and hypothalamus, while UCH-L3 expression was somewhat higher in the testis. The occurrence of mutation rates in UCHs also suggests that BAP1 and UCH-L5 may play a more dominant role in cancers than UCH-L1 and UCH-L3. We also characterized the functional context and configuration of the repeat elements in the promoter of DUBs genes and found that UCHs are highly discriminatory for catabolic function and are mainly enriched with LINE/CR1 repeats. Regarding the thesis of an inverse association between cancer and NDD, we observed that among all DUBs, UCHs are the one most involved in both entities. Considering a putative therapeutic potential based on presumed common mechanisms, it will be useful to determine whether other DUBs can compensate for the loss of UCH activity under physiological conditions. However, experimental evidence is required to substantiate this argument.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Databases, Genetic
|2 MeSH
650 _ 2 |a Gene Expression Profiling
|2 MeSH
650 _ 2 |a Gene Expression Regulation
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neoplasms: enzymology
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: enzymology
|2 MeSH
650 _ 2 |a Phenotype
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Protein Domains
|2 MeSH
650 _ 2 |a Tumor Suppressor Proteins: metabolism
|2 MeSH
650 _ 2 |a Ubiquitin Thiolesterase: genetics
|2 MeSH
650 _ 2 |a Ubiquitin Thiolesterase: metabolism
|2 MeSH
650 _ 2 |a Ubiquitination
|2 MeSH
700 1 _ |a Liu, Hongde
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Tobar-Tosse, Fabian
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Chand Dakal, Tikam
|b 3
700 1 _ |a Ludwig, Michael
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Holz, Frank G
|b 5
700 1 _ |a Loeffler, Karin U
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Wüllner, Ullrich
|0 P:(DE-2719)2000056
|b 7
|u dzne
700 1 _ |a Herwig-Carl, Martina C
|0 P:(DE-HGF)0
|b 8
|e Corresponding author
773 _ _ |a 10.3390/ijms21113910
|g Vol. 21, no. 11, p. 3910 -
|0 PERI:(DE-600)2019364-6
|n 11
|p 3910 -
|t International journal of molecular sciences
|v 21
|y 2020
|x 1422-0067
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/153373/files/ijms-21-03910.pdf
856 4 _ |y OpenAccess
|x icon
|u https://pub.dzne.de/record/153373/files/ijms-21-03910.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://pub.dzne.de/record/153373/files/ijms-21-03910.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://pub.dzne.de/record/153373/files/ijms-21-03910.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://pub.dzne.de/record/153373/files/ijms-21-03910.jpg?subformat=icon-640
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/153373/files/ijms-21-03910.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:153373
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2000056
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|2 G:(DE-HGF)POF3-300
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2020
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-09
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-09
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-09
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-09-04T08:27:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-09-04T08:27:04Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-09-04T08:27:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J MOL SCI : 2021
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2022-11-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J MOL SCI : 2021
|d 2022-11-25
920 1 _ |0 I:(DE-2719)1011302
|k AG Wüllner ; AG Wüllner 2
|l Biomarkers for Parkinson's disease
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011302
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21